.After a handful of years in biotech, Mike Quigley, Ph.D., is returning to the pharma layer, taking up the leading scientific research area at Sanofi.Quigley is going to begin Sept. 30 as the French Big Pharma’s primary scientific officer as well as worldwide director of study, Sanofi said to Fierce Biotech in an emailed statement.Quigley is changing Frank Nestle, M.D., who left behind Sanofi this spring amid a global overhaul of the business’s R&D system. Nestle, that devoted eight years along with the pharma, leapt over to Deerfield Management, where he presently serves as a companion on the therapeutics crew and also CEO of the firm’s restorative discovery and progression operations.
Quigley will definitely join Sanofi coming from a San Francisco-based biotech that resides in stealth, according to his LinkedIn account. He’s presently noted as the provider’s founder, president and also CEO.Due to the fact that August 2021, Quigley has actually acted as a venture companion at SV Health Investors, a health care fund manager along with present expenditures in biotechs including BioAge, Cerevance, Dualitas Therapies and Nimbus Therapies, among others. Quigley in the past held the leading place at Dualitas, a biotech that remains in secrecy, depending on to STAT.The prospective Sanofi leader likewise recently helmed Therini Bio, an immunotherapy biotech operating to establish procedures for neurodegenerative conditions steered through general dysfunction.Before devoting the final handful of years in biotech, Quigley possesses an even longer record in Big Pharma, very most recently functioning as Gilead’s elderly bad habit head of state of investigation the field of biology until the summer months of 2021.
Before that, he appeared much more than 4 years around a variety of leadership roles at Bristol Myers Squibb as well as acted as a scientific director at Johnson & Johnson’s Janssen upper arm before that.Sanofi said Quigley’s objective in his brand new part will be actually to “maximize our possibility of results through optimum partnerships around our institution and past, bringing best-in-class innovation and also building and sourcing brand new industry-leading ability with a devotion to range,” according to an interior memorandum acquired through STAT.